Q4 Review: Biocon's Kiran Mazumdar Shaw On Earnings & FY23 Projections

2022-04-29 19 Dailymotion

#Q4WithBQ | Biocon's Q4 net profit surpasses estimate but margins see a contraction on a yearly basis.
Executive Chairperson Kiran Mazumdar Shaw shares growth projections for FY23 along with strategies to boost growth. #BQLive

Related Videos

Q2WithBQ With Biocon's Kiran Mazumdar Shaw

Profit Insights | Biocon's Kiran Mazumdar Shaw Exclusive | NDTV Profit

Biocon’s Kiran Mazumdar Shaw On Who’ll Win The Battle Between ‘Innovators’ And Biosimilar Makers

Corporate tax cut is a much needed reform, says Biocon's Kiran Mazumdar Shaw

Interview: Biocon MD, Kiran Mazumdar Shaw

Kiran Mazumdar Shaw of Biocon on business outlook

Allow companies to provide booster doses to employees: Biocon chief Kiran Mazumdar-Shaw | EXCLUSIVE

Kiran Mazumdar-Shaw: Australia, New Zealand & Europe Will Be Strong Markets For Biocon

Don't think the budget has moved the needle in improving consumption, says Kiran Mazumdar Shaw of Biocon

Kiran Mazumdar Shaw of Biocon on biosimilar & business outlook